Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

NCT01896830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL: Clostridium difficile Toxoid Vaccine
BIOLOGICAL: 0.9% normal saline

Sponsor

Sanofi Pasteur, a Sanofi Company